mRNA new drug enterprise, planning to list on the Hong Kong Stock Exchange: laying out the plan for in vivo CAR-T
2025-10-27
Recently, BioNTech, a pharmaceutical company from the Greater Bay Area specializing in mRNA drugs, plans to go public through an IPO in Hong Kong, China. The listing could take place as early as next year, potentially raising approximately US$200 million.
MORE